Brusselsspirit, I am not concerned about Citron as Anip has much more flexibility when it comes to pricing. Mallinckrodt paid $5.2 billion for Questcor to a quire Acthar. Anip paid $75 million and future royalties to Merck for the Corti drugs.
Anip intended to sell at a discount Mallinckrodt. I think they will find an acceptable price point. They have much more pricing flexibility to ensure a ROI.
In any event most hear feel Corti is the first of a number of catalysts coming down the pipe.
Personally, I am here for what the company does not advertise. Including a potential co-promotion deal with Abbvie on Libigel.
- $2.4 billion in revenue by simply switching existing off label and compounded testosterone presently being prescribed for HSDD. - The future growth for HSDD once an FDA drug is approved. - The yet to be announced discovery that Testosterone restoration in at risk post menopausal women reduces the number of cardiovascular events by at least 70%. - Most likely target audience - Hypertension and Dyslipidemia (Only available in patent applications) - Future indications may also include breast cancer reduction. As was also discovered during the larger 3656 patient saftey/efficay study. Once again this has not been released publicly as of yet. (Only available in patent applications)
Anip also owns a stake (approx.15%)+ I believe milestone payments and Royalties in Cold Genesys who are completing their phase 3 Bladder Cancer trial Primary Completion June 2017.
News 
Market Data 
Discover 
